DCM
VRTX icon

Delpha Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Delpha Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-213
Closed -$32K – 1189
2017
Q4 		$32K Buy
+213
New +$31.5K 0.03% 534

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Delpha Capital Management's VRTX Position: Q1 2018 in Review

Delpha Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2018, closing a stake of 213 shares — an estimated $32K sold.

Delpha Capital Management first reported a position in VRTX in Q4 2017 and held it in 1 quarter. The position peaked at $32K in Q4 2017. 681 funds tracked by Wall St. Rank hold VRTX as of Q1 2018.

  • Delpha Capital Management reported no remaining Vertex Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 213 Vertex Pharmaceuticals shares in Q1 2018, an estimated $32K.
  • Delpha Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Vertex Pharmaceuticals position peaked at $32K in Q4 2017.
  • 681 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.